evipedia.ai
← Back

Green Light Therapy for Hair Regrowth

Evidence Review created on 08/24/2026 using AI4L / Opus 5

Also known as: Green LED Therapy, Green Light Photobiomodulation, Green-Wavelength Low-Level Light Therapy, 520 nm Photobiomodulation, Green Laser Therapy

Motivation

Green light therapy shines low-power light from the green part of the visible spectrum — roughly 515 to 530 nanometers — onto the scalp, usually from a helmet or cap fitted with small semiconductor lamps. It belongs to a family of light treatments in which light is absorbed inside cells and changes how they work, rather than heating or cutting tissue. The green band is a newcomer here.

For two decades the devices sold and studied for thinning hair have emitted red or near-infrared light instead. Pattern hair loss reaches about half of men by their fifties and many women after menopause, and the available medicines carry side-effect and daily-use burdens that push many people toward device-based options. Interest in green wavelengths grew after animal work hinted that they might rouse resting follicles at least as readily as red.

This review examines what is known about green light aimed at the scalp for hair regrowth: how it is proposed to act, what the human and animal evidence shows and where it stops, what risks and practical limits come with it, and how it compares with the better-studied red approach.

Benefits - Risks - Protocol - Conclusion

The following resources give a high-level overview of photobiomodulation — the use of low-power red, green, or near-infrared light to change how cells behave rather than to heat or cut tissue — and of its application to hair regrowth.

Note on priority experts: no relevant content was found on chriskresser.com or lifespan.io. Neither platform carries an overview of light therapy or photobiomodulation as a treatment category; chriskresser.com returns only near-infrared sauna and seasonal-light material, and lifespan.io only single news items on infrared lasers in animals.

Grokipedia

  • Green light therapy for migraine

    Grokipedia’s only dedicated green-light page. It describes narrow-band 520–525 nm exposure and its effects on photophobia (painful sensitivity to light) and headache, but nothing on scalp application.

Examine

No Examine article exists for green light therapy. Examine’s coverage is built around ingestible supplements, foods, and nutrients, and it does not maintain pages for light-emitting devices or other physical modalities.

ConsumerLab

No ConsumerLab article exists for green light therapy. ConsumerLab tests ingestible products for identity, potency, and contamination; its light-therapy coverage is limited to red and near-infrared devices and light boxes, with no green-wavelength entry.

Systematic Reviews

The systematic reviews and meta-analyses below cover low-level laser and light-emitting diode (LED) therapy for pattern hair loss (androgenetic alopecia, the inherited progressive thinning that follows a receding-hairline or crown pattern); none is specific to green wavelengths, because none exists.

Trade-off note: the claimed effect (hair regrowth from scalp light) is well represented above, and the principal forgone benefit (using red or near-infrared light instead) is directly addressed by the waveband review. The principal risk side is unrepresented: no systematic review or meta-analysis exists on visible-light-induced pigment change, ocular exposure, or any other harm from scalp light devices, and none exists on green-wavelength photobiomodulation of any tissue for hair.

Mechanism of Action

Red and near-infrared photobiomodulation is generally attributed to cytochrome c oxidase (the final enzyme of the mitochondrial energy chain), which absorbs strongly between roughly 620 and 850 nm and, once photoexcited, raises output of adenosine triphosphate (ATP, the cell’s energy currency). Green light near 520 nm sits in a trough of that absorption, so a different account is needed. Serrage and colleagues propose that green photons are captured instead by flavins and porphyrins (light-absorbing molecules already present in cells) and by opsins such as OPN3 (a light-sensing receptor protein expressed in skin), generating reactive oxygen species (chemically reactive oxygen-containing molecules that act as signals) and calcium entry through TRPV1 (an irritant- and heat-gated pore in the cell membrane).

Downstream, work on dermal papilla cells — the cluster at the follicle base that directs growth — links photobiomodulation to activation of Wnt/β-catenin signalling (the pathway that pushes follicles from rest into growth) and suppression of transforming growth factor beta (TGF-β, a brake on follicle growth).

A competing reading exists. In human stem cells, 540 nm light lowered ATP and mitochondrial membrane potential and inhibited proliferation through that same TRPV1–calcium–reactive-oxygen route, while red and near-infrared stimulated it. Green is also absorbed heavily by melanin and haemoglobin, so less of it reaches follicle stem cells one to four millimetres down — the stated rationale for light-guiding microneedle delivery, developed by a group that co-designed the hardware it tested.

Historical Context & Evolution

Photobiomodulation began as an accident. In the late 1960s the Hungarian surgeon Endre Mester, testing whether a ruby laser would cause tumours in shaved mice, found instead that irradiated animals regrew hair faster than controls, as recounted in a review of the field.

Development then ran almost entirely through red and near-infrared wavelengths, on the reasoning that cytochrome c oxidase was the receiving molecule and that longer wavelengths penetrate further. The first hand-held device for hereditary hair loss cleared United States regulators in 2007 at 655 nm, and the cleared products that followed used 655 or 678 nm.

Green light developed on a separate track, in pain medicine. Exposure to narrow-band green light reduced headache days in a small crossover study, establishing that green wavelengths carry effects of their own.

The two tracks met in 2022, when a Thai group irradiated mouse skin with red, green, and blue light and reported that green produced the largest hair-growth response of the three. The same group then ran two small split-scalp studies in people. Its devices were co-developed with a state nanotechnology agency, so the only human green-light hair data come from parties invested in the hardware.

A 2025 expert consensus endorses photobiomodulation for hereditary hair loss, but the trials it rests on are red and near-infrared, and its panel is drawn from dermatologists whose practices offer these procedures. What changed since 2022 is the animal signal, not the human evidence base.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the only human evidence is two small split-scalp series without a sham (dummy-device) or untreated arm, so no outcome has been shown against a control even once, let alone in more than one trial.

Medium 🟩 🟩

No benefit reaches Medium either: there is no single controlled human trial of green scalp light against sham or no treatment, and no observational cohort of any size has followed green-wavelength device users.

Low 🟩

Increased Terminal Hair Density

Green-lit scalp halves gained thick, pigmented terminal hairs over 24–26 weeks in two small split-scalp studies (17 and 16 adults with pattern hair loss). Neither carried a sham arm, so regression to the mean and seasonal cycling remain uncontrolled. Both came from one group.

Magnitude: Both reports state that non-vellus (thick, pigmented rather than fine and colourless) hair density rose significantly on the green-lit half at 40 J/cm² per session — joules of energy delivered per square centimetre of scalp — sustained over six months; neither publishes an absolute hairs-per-square-centimetre change, so the literature reports no outcome figure.

Increased Hair Shaft Diameter

Average shaft thickness rose on green-lit halves in the same two studies. In the helmet comparison the red half gained significantly more diameter than the green; with a microneedle patch added, the two wavelengths were indistinguishable. The presumed mechanism is partial reversal of follicle shrinkage.

Magnitude: Direction is positive and holds at 40 J/cm² per session across 24–26 weeks, with red outperforming green when light alone is used; the reports give no micrometre change figure, so the literature reports no outcome figure.

Investigator- and Self-Rated Scalp Coverage

Physician seven-point global ratings and participant satisfaction scores both improved on green-lit halves and kept rising month over month in the helmet study. This is a rater-judged endpoint, distinct from the counted measures above, and the one most exposed to expectation effects in an unblinded design.

Magnitude: Ratings moved upward at every monthly timepoint at 40 J/cm² per session; neither report gives a mean score change, so the literature reports no outcome figure.

Speculative 🟨

Faster Shift From Resting to Growing Follicle Phase

In shaved mice, 513 nm green light drove more follicles from the resting phase into the growing phase than red or blue. Basis is animal only; no human study has measured this shift.

More Follicles and New Blood Vessels in Treated Skin

Mouse skin biopsies after green light with a microneedle patch showed more follicles, denser collagen, and new small vessels. Animal histology only; no human biopsy data exist for green scalp light.

Benefit-Modifying Factors

  • Androgen-pathway genetics: Variants at the AR/EDA2R locus (the androgen receptor region, the strongest known pattern-hair-loss signal) and in SRD5A2 (the gene for 5α-reductase, which converts testosterone to its more potent scalp form) set how much reversible follicle remains for light.

  • Pigmentation genetics: MC1R and related pigment genes (they set how much melanin skin makes) govern how much green light is absorbed in the epidermis before reaching the follicle. Darker scalps receive proportionally less green light at depth than red.

  • Baseline biomarkers: Low ferritin (the stored-iron protein), low vitamin D, and untreated thyroid dysfunction each prolong the resting phase independently of androgens. Shedding driven by these will not respond to light until the deficit is corrected.

  • Sex: Both split-scalp studies enrolled men and women and neither reported results by sex. Female pattern loss is diffuse with a preserved hairline, so uniform helmet coverage may suit it better than the frontal-recession target used in those studies.

  • Pre-existing conditions: Scarring alopecias (permanent follicle destruction with fibrous replacement) leave nothing to stimulate. Active seborrhoeic dermatitis (inflamed, flaking dandruff-type rash) or psoriasis on the scalp adds scale that scatters light before it enters the skin.

  • Age: Older adults hold fewer surviving follicles and spend longer in the resting phase, lowering the ceiling. Grey and white hair contains little melanin, so more green light passes the shaft — a plausible offsetting advantage, untested.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the only human adverse-event data are self-reported mild scalp effects from a single small trial, so no harm has been documented in the more than one trial that a High grade requires.

Medium 🟥 🟥

Transient Scalp Warmth and Redness

Participants in the red/green helmet study reported tolerable scalp heat and mild redness, the only adverse effects recorded. The cause is straightforward optical absorption and local heating at roughly 50 mW/cm² (milliwatts of light power per square centimetre of scalp) for 20 minutes. Effects were self-limiting and did not interrupt treatment. This is documented in one trial of 17 adults; the microneedle-patch trial reported no serious adverse effects but did not tabulate minor ones.

Magnitude: Present but unquantified — heat and redness are described as tolerable and self-limiting at 40 J/cm² per 20-minute session, and no incidence rate is given, so the literature reports no outcome figure.

Low 🟥

Pigment Darkening in Richly Pigmented Skin

Visible light between 400 and 700 nm produces long-lasting darkening in Fitzpatrick skin types IV–VI (the scale of how skin responds to sun, from always-burns to never-burns), and green sits where melanin absorbs most strongly. No green scalp device has been tested for this; the inference is indirect.

Magnitude: Direction is toward darkening, and it holds only where scalp skin is exposed and pigment-rich — hairline, part line, bald crown in types IV–VI; no study has measured pigment change from a green scalp device, so the literature reports no outcome figure.

Smaller Shaft-Thickness Gain Than Red Light ⚠️ Conflicted

The helmet study found red significantly better than green for shaft diameter; the microneedle-patch study found no difference. The patch confounds that comparison by adding mechanical injury. Net reading: green is probably no better than red, and likely worse when light travels alone.

Magnitude: Direction favours red at 40 J/cm² over six months with light alone, and the gap closes once a microneedle patch is added; neither report gives a between-arm difference figure, so the literature reports no outcome figure.

Eye Injury From Laser-Class Green Devices

Handheld 532 nm green lasers have burned the retina in documented cases, some with lasting central vision loss. Light-emitting diode helmets are far weaker and scattered, but laser-based scalp caps concentrate power. Evidence is case reports only.

Magnitude: Injuries are documented but confined to direct beam exposure from laser sources rather than diode helmets used as directed; the case literature gives no incidence rate, so it reports no outcome figure.

Flare of Light-Triggered Skin Disease

Solar urticaria (hives provoked by light), chronic actinic dermatitis (a persistent light-driven eczema), and melasma (patchy darkening) can be provoked by visible wavelengths. Green scalp devices have not been studied in these groups; risk is inferred from broader visible-light data.

Magnitude: Direction is toward flare, and it holds only in people already diagnosed with a visible-light-triggered disorder; no study has exposed such patients to a green scalp device, so the literature reports no outcome figure.

Evening Melatonin Suppression and Delayed Circadian Timing

Green at 515–530 nm sits near the peak sensitivity of melanopsin (the eye’s circadian pigment), so evening scatter into the eyes can suppress melatonin and delay the body clock. Late-night 525 nm light did both in healthy adults; sleep was not measured. Eye-level dose from a scalp device is unmeasured.

Magnitude: Two hours of light after midnight produced 65–81% salivary melatonin suppression and a 27–36 minute delay in melatonin onset across the three shortest wavelengths tested, 525 nm among them; no study has measured what reaches the eye from a scalp helmet.

Speculative 🟨

Suppression of Cell Proliferation at Green Wavelengths

In human adipose-derived stem cells, 540 nm light lowered cellular energy output and mitochondrial membrane potential and inhibited proliferation, while red and near-infrared stimulated it. Cell-culture basis only; no human follicle data.

Risk-Modifying Factors

  • Pigmentation and porphyrin genetics: MC1R variants raise baseline melanin and with it green-light absorption. Ferrochelatase variants (the last enzyme of haem synthesis) cause erythropoietic protoporphyria (skin loaded with porphyrins that absorb visible light and produce burning pain on exposure).

  • Baseline biomarkers: Baseline melanin index or recorded Fitzpatrick phototype predicts pigment-darkening risk better than self-described skin colour. Where unexplained photosensitivity is present, plasma and erythrocyte porphyrin levels are the measurements that identify a porphyria before exposure.

  • Sex: Melasma is several times more common in women, particularly during pregnancy or with oestrogen-containing contraception, so the pigment-darkening risk of visible light falls disproportionately on women with mid-range to darker phototypes.

  • Pre-existing conditions: Photodermatoses (skin diseases triggered by light), cutaneous lupus, melasma, recent scalp resurfacing, and photosensitive epilepsy (seizures triggered by flickering light) all raise risk, as does an unassessed pigmented lesion inside the treatment field.

  • Age: Older scalps carry more sun damage and more pigmented lesions, and older adults take more photosensitising medicines. Lens changes and cataract surgery alter how much scattered visible light reaches the retina.

Key Interactions & Contraindications

  • Photosensitising prescription drugs: Tetracycline antibiotics (doxycycline, minocycline), amiodarone, thiazide diuretics (drugs that increase urine output, such as hydrochlorothiazide), voriconazole, isotretinoin, and methoxsalen. Severity: caution. Consequence: exaggerated redness, burning, or lasting pigment darkening. Mitigation: separate courses, or halve session time and photograph the scalp weekly.

  • Photodynamic therapy agents: Topical 5-aminolevulinic acid or methyl aminolevulinate (drugs that load skin with light-activated porphyrins before a clinic light treatment). Severity: absolute contraindication within 48 hours of application. Consequence: phototoxic burn with blistering. Mitigation: defer all scalp light for at least 48 hours.

  • Over-the-counter medication interactions: Topical ketoprofen and piroxicam gels and oral St John’s wort (which contains the light-activated pigment hypericin) each raise light sensitivity. Severity: caution. Consequence: exaggerated redness. Mitigation: apply topical agents only after the session, never before.

  • Supplement interactions: High-dose riboflavin (vitamin B2, a flavin that absorbs green light directly) and chlorophyll or chlorella preparations containing pheophorbide are theoretically photosensitising. Severity: caution. Consequence: increased redness. Mitigation: dose in the evening, well separated from a morning session.

  • Supplements with additive effects: Saw palmetto, pumpkin seed oil, and topical caffeine all act on the androgen pathway rather than the light pathway, so effects should add rather than overlap. Severity: no interaction expected. Consequence: none identified. Mitigation: none required.

  • Other intervention interactions: Topical minoxidil, microneedling, and platelet-rich plasma (concentrated plasma from a person’s own blood, injected into the scalp) combine additively with light therapy in the red-wavelength literature. Severity: monitor. Consequence: additive irritation. Mitigation: apply minoxidil after, not before, irradiation.

Populations who should avoid Green Light Therapy:

  • Anyone with a pigmented scalp lesion, melanoma, or dysplastic naevus (an atypical mole) inside the treatment field, until it has been assessed and cleared.

  • Cutaneous porphyrias — erythropoietic protoporphyria, porphyria cutanea tarda — and xeroderma pigmentosum (an inherited failure to repair light damage to DNA).

  • Diagnosed photodermatoses: solar urticaria, chronic actinic dermatitis, and photosensitive cutaneous lupus erythematosus with active disease.

  • Anyone within 48 hours of photodynamic therapy, or taking a photosensitising drug at full therapeutic dose without dermatological supervision.

  • Photosensitive epilepsy where flicker in the 3–60 Hz band provokes seizures, if the device pulses rather than emitting continuously.

  • Fitzpatrick phototype V–VI with active melasma or post-inflammatory darkening on visible scalp skin.

Risk Mitigation Strategies

  • Wavelength-rated eye protection: With laser-class devices, goggles rated optical density 4 or higher at 532 nm worn for the whole session, and an otherwise empty room, are what prevent retinal burn and lasting central vision loss.

  • Phototype-graded ramp-up: In Fitzpatrick types IV–VI, half the manufacturer’s session time for the first two weeks, with monthly fixed-lighting photographs of the hairline and part, prevents unnoticed accumulation of pigment darkening.

  • Fluence ceiling: Delivered energy at or below 40 J/cm² per session, at roughly 50 mW/cm², two to three sessions weekly, stays inside the studied range and prevents the scalp heating and redness reported at higher exposure.

  • Photosensitiser separation: A pause of at least five half-lives of any photosensitising drug, and of at least 48 hours after photodynamic therapy, prevents phototoxic burn and blistering.

  • Morning-only scheduling: Sessions completed before midday prevent evening suppression of melatonin by scattered green light, which sits close to the peak sensitivity of the eye’s circadian receptor.

  • Baseline scalp examination: A dermatological assessment before the first session — diagnosis confirmed, scarring alopecia excluded, pigmented lesions checked — prevents months spent irradiating destroyed follicles and prevents irradiating an unrecognised skin cancer.

Therapeutic Protocol

  • Core parameters: The only published human protocol delivers 515–530 nm at roughly 50 mW/cm² to a fluence of 40 J/cm², about 20 minutes per session, over 24–26 weeks. Sessions ran weekly to three times weekly.

  • Approach one — green light alone: A helmet or cap seats diodes at fixed distance over the frontal and vertex scalp. Popularised by Jitlada Meephansan’s group at Thammasat University with Thailand’s National Nanotechnology Center, who built the prototypes.

  • Approach two — green light with a light-guiding microneedle patch: The same helmet illuminates a patch of 900 µm needles at 105 per square centimetre, carrying light past the epidermis. Same group; adds mechanical stimulation and cost.

  • Approach three — red or near-infrared light: Cleared home devices emit 655 or 678 nm, typically 15–30 minutes every other day. Marketed by Lexington International, Theradome, iRestore, and Capillus, each of which sponsored its own clearance trial.

  • Pharmacokinetics do not apply: Light has no half-life and no split-dose question, since nothing accumulates in tissue. The device analogue is the biphasic dose response: too little energy does nothing, too much reverses the effect.

  • Best time of day: Morning. Green sits near the peak sensitivity of melanopsin, the eye’s circadian pigment, so scattered light from an evening session can delay sleep onset without adding hair benefit.

  • Genetic influences on protocol: Darker-pigmented scalps (driven by MC1R and related variants) absorb more green light superficially, favouring the microneedle-patch route or a red device. SRD5A2 and AR/EDA2R variants predict how much follicle remains responsive.

  • Sex-based differences: Neither published study reported outcomes by sex, so no sex-specific parameters exist. Women with diffuse thinning need whole-scalp coverage rather than the frontal-recession field both studies treated.

  • Age considerations: Past 60 the ceiling is lower and the runway longer, since fewer follicles remain cyclable. Cataract surgery or lens implants change scattered-light exposure and strengthen the case for morning-only sessions.

  • Baseline biomarkers: Ferritin, vitamin D, zinc, and thyroid status are corrected before the device is judged, since deficiency-driven shedding otherwise masks or mimics any light effect over the first three months.

  • Pre-existing conditions: Confirmed scarring alopecia predicts no response and argues against starting. Active scalp psoriasis or seborrhoeic dermatitis is treated first in practice, so that scale does not scatter light at the surface.

Discontinuation & Cycling

  • Intended duration: Continuous and open-ended. Both published studies ran 24–26 weeks with gains still accruing at the end, and neither followed participants after stopping, so durability is unknown.

  • Withdrawal effects: None described. By analogy with the red-wavelength literature, the expected pattern is gradual loss of gained density over three to six months rather than an accelerated shed.

  • Tapering: No pharmacological taper applies. Users who stop typically step down to one session weekly as a maintenance schedule, though no study has tested whether reduced frequency preserves gains.

  • Cycling: No evidence supports cycling, and the biphasic dose response argues against escalating exposure during “on” blocks. Consistency at a fixed fluence has better support than any planned interruption.

Sourcing and Quality

  • Regulatory reality first: No green-wavelength scalp device holds clearance for hair growth anywhere. Every cleared low-level light hair device emits 655 or 678 nm red. Green units are sold as general-wellness or cosmetic products, outside medical-device oversight.

  • Emission spectrum: What identifies a genuine green device is peak wavelength with tolerance (for example 522 ± 10 nm) and spectral bandwidth from an independent photometric report. Many consumer “green” panels are broad-spectrum white behind a green filter, delivering a fraction of the stated dose.

  • Irradiance at the scalp, not at the diode: The specification that matters is milliwatts per square centimetre measured at the scalp-to-diode distance the helmet imposes. Without it, session time cannot be converted into delivered energy.

  • Third-party testing: For a device this means independent optical measurement and an electrical safety certificate, not a certificate of analysis. The test house name and report date are what distinguish it from a marketing claim of “clinically proven”.

  • Named products and their limits: The red-wavelength market has cleared products with published trials — HairMax, Theradome, iRestore, Capillus. The green helmet and microneedle patch used in the human studies were National Nanotechnology Center research prototypes and are not sold.

Practical Considerations

  • Time to effect: Nothing is visible before 12 weeks. In both published studies, density and diameter separated from baseline between three and six months, and ratings were still improving at the endpoint, so six months is the minimum fair trial.

  • Common pitfall — inconsistent use: Skipping sessions is the dominant failure mode across the whole light-therapy literature. A helmet used twice weekly for six months beats one used daily for six weeks and then abandoned in a drawer.

  • Common pitfall — treating dead zones: Fully bald scalp with no visible fine hair holds no follicles to stimulate. Light therapy of any wavelength works on miniaturised follicles, not on skin where the follicle has already been replaced by fibrous tissue.

  • Common pitfall — buying on colour alone: A green LED panel sold for skin tone or mood carries no relationship to the 40 J/cm² scalp protocol. Without irradiance and wavelength specifications, session time is meaningless.

  • Regulatory status: Use is entirely off-label and unregulated for this purpose. In the United States a green scalp device is a general-wellness product; in the European Union no green device carries a medical claim for hair.

  • Payer position and its evidence effect: No insurer or national health system covers hair-loss devices of any wavelength, since pattern hair loss is classed as cosmetic. That removes any public research funding, leaving device manufacturers as the near-exclusive sponsors of trials in the field.

  • Cost and accessibility: Green is effectively unavailable as a validated product; the studied hardware was a research prototype. Anyone wanting green wavelengths today must buy an unspecified consumer panel or wait, whereas red caps cost several hundred to two thousand dollars.

Interaction with Foundational Habits

  • Sleep: Direct and potentially disruptive. Green at 515–530 nm sits near the peak sensitivity of melanopsin, the eye’s circadian pigment, so evening scatter into the eyes can suppress melatonin and delay sleep onset. In practice this places sessions before midday, or behind opaque eye covers.

  • Nutrition: Indirect and permissive. Light does not deplete any nutrient, but iron stores, protein, zinc, and vitamin D gate how far a follicle can respond. In practice low ferritin is corrected first and crash dieting avoided during the trial, since rapid weight loss triggers shedding that reads as device failure.

  • Exercise: Essentially none in either direction. The blunting concern that applies to high-dose antioxidant supplements does not transfer to scalp light. The one practical link is optical: sweat, sunscreen, and styling product scatter green light at the surface, so a clean dry scalp precedes the session rather than follows a training block.

  • Stress management: Indirect. Psychological stress drives diffuse shedding, which can swamp any device effect and is a common reason a six-month trial reads as a failure. No data connect green light exposure to cortisol or the stress response, so stress-driven shedding stands as a separate problem from the one the device addresses.

Monitoring Protocol & Defining Success

Baseline assessment before the first session rests on two independent measures. The laboratory baseline rules out the non-androgen drivers of shedding that would otherwise be credited to, or blamed on, the device: iron stores, vitamin D, thyroid function, zinc, and adrenal androgens. The visual baseline is a set of standardised photographs — same lighting, same part line, same distance — plus a trichoscopic hair count (magnified scalp imaging) at a marked reference point, since recalled impressions of hair density are unreliable.

The laboratory panel is repeated at three months where any value was abnormal at baseline, otherwise at six to twelve months. Photographs and the trichoscopic count are repeated at 4, 12, and 24 weeks, then every six months. The device is judged at 24 weeks, against the counted baseline rather than against memory.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Ferritin 70–100 ng/mL (women), 100–150 ng/mL (men) Low iron stores prolong the resting phase and cap any regrowth response Conventional labs flag deficiency only below 15–30 ng/mL; ferritin rises with inflammation, so pair with high-sensitivity C-reactive protein (CRP, a general marker of inflammation)
25-Hydroxyvitamin D 40–60 ng/mL Deficiency is repeatedly associated with pattern and patchy hair loss Conventional sufficiency begins at 30 ng/mL; no fasting needed; recheck 3 months after any dose change
Thyroid-stimulating hormone (TSH) 0.5–2.0 mIU/L Both under- and overactive thyroid cause diffuse shedding that mimics device failure TSH is the pituitary signal that drives the thyroid. Conventional range extends to 4.0–4.5 mIU/L; draw in the morning before any thyroid dose; pair with free thyroxine and free triiodothyronine
Serum zinc 90–120 µg/dL Zinc is required for follicle protein synthesis and is depleted by chronic dieting Conventional ranges start near 60–70 µg/dL, so a “normal” result can still sit below the functional target; fasting morning draw; haemolysed samples read falsely high; pair with serum copper, since supplementation shifts the ratio
Dehydroepiandrosterone sulfate (DHEA-S) 200–400 µg/dL (men), 150–300 µg/dL (women) Adrenal androgen excess drives follicle shrinkage independently of testicular or ovarian output DHEA-S is the main adrenal androgen precursor. Conventional ranges are wide and age-banded; morning draw; in women, pair with total testosterone if there is also acne or unwanted facial hair
Trichoscopic hair density at a marked reference point No established target exists; track change from the individual’s own baseline, aiming for any rise by 24 weeks The only direct measure of whether the device is doing anything Use the same magnification, site, and device each time; count terminal and vellus hairs separately, as the earliest signal is a shift between them

Qualitative markers worth tracking alongside the numbers:

  • Hair shed on the pillow and in the shower drain, counted roughly rather than precisely, on the same two days each month.

  • Whether a gentle hair-pull test at the crown and temples yields more than a few hairs.

  • Styling volume and ponytail circumference, which often shift before a hair count does.

  • Scalp comfort during and after sessions — warmth, tightness, itch, or tenderness.

  • Sleep onset latency in the weeks after starting, as a check on evening light exposure.

Emerging Research

  • No green hair trial is registered: A registry search returns 65 light-based alopecia studies and none using green wavelengths. Until one is registered, the human evidence base cannot grow beyond the two split-scalp series already published.

  • Commercial photobiomodulation device evaluation (NCT06403644): United States Air Force Research Laboratory, 41 participants, active and not recruiting. Sham-controlled crossover comparing two commercial light beds at roughly 30 and 75 mW/cm², a controlled read on whether delivered irradiance changes biological effect — the parameter least documented for green units.

  • Fractional non-ablative laser for hair loss in skin of colour (NCT06885112): Lumenis, 40 participants, recruiting. The only active hair-device trial recruiting specifically in richly pigmented skin, where green light’s pigment-darkening risk is greatest.

  • Minoxidil with or without low-level red-light therapy in chemotherapy-induced hair loss (NCT07594678): Ohio State University, Phase 2, 50 breast cancer patients, not yet recruiting. A properly controlled test of whether light adds anything to a drug — the design green light has never received.

  • Could strengthen the case — light-guiding delivery: Charoensuksira et al., 2024 showed green matching red once a microneedle patch carried light past the epidermis, suggesting green’s weakness is depth of penetration rather than biology.

  • Could strengthen the case — pulsed parameters: Ren et al., 2025 found pulse frequency, not dose, was the decisive parameter in follicle papilla cells. Every green human study to date used continuous light, so the parameter space is unexplored.

  • Could weaken the case — wavelength-specific inhibition: Wang et al., 2017 found 540 nm light suppressed stem-cell proliferation while red stimulated it. Replication in follicle stem cells would undercut the mechanistic case entirely.

  • Could weaken the case — waveband pooling: Zhang et al., 2022 found effects for red and infrared but had no green studies to pool. Any future update that includes green will settle the comparison one way or the other.

Conclusion

Green light therapy puts low-power light from the green part of the visible spectrum onto the scalp, most often through a helmet fitted with small semiconductor lamps. The case for it rests on an animal study in which green outperformed red and blue, and on two small human studies in which scalp areas treated with green light gained thicker, denser hair over about six months. Neither human study included a dummy-treated area, both came from the same research team, and that team helped build the devices it tested. Against that sit laboratory findings in which green light slowed cell growth where red light sped it up, and the fact that every device approved for hair loss emits red or near-infrared light instead.

Reported harms are mild — scalp warmth and redness — with the more plausible concerns being darkening of pigment-rich scalp skin, eye injury from laser-based rather than lamp-based units, and flares in people with light-triggered skin disease. Because hair loss is treated as a cosmetic matter, no public health system funds work in this area, so almost every trial is paid for by a device maker, and the expert panel that endorses light treatment for hair loss is drawn from clinicians whose practices offer it. Weighed against the alternatives, green sits well behind red on evidence, and the human record is thin enough that its true effect could be anywhere from modest to nothing at all.

Top - Benefits - Risks - Protocol